Alliances between pharmaceutical companies can take a number of forms to accommodate the strategic interests of the partnering firms. These alliances also occur at different stages in the product lifecycle, from early stage product development, to late stage development to the sales and marketing of an approved product, and even occur once a product is approaching or reaches patent expiry. CRA’s Life Sciences Practice has been asked to assess the value of different types of marketing alliances.
Counting the cost of carbon to shareholders: Taking first steps
Companies are facing the prospect of being taxed on greenhouse gas (GHG) emissions, which could reduce profitability and, ultimately, shareholder value. Our...